NEW YORK, October 31, 2016 /PRNewswire/ --
http://www.Financialbuzz.com - Tobacco smoking is the leading cause of avoidable death in the US, and chronic exposure to tobacco smoke is related to increased incidences of cancer as well as vascular disease, according to the United States Center for Disease Control. Many substitutes have been created to help individuals quit smoking cigarettes, such as herbal cigarettes, e-cigs, vaping, specialized gum, and many other ways. CV Sciences Inc. (OTC: CVSI), Insys Therapeutics Inc. (NASDAQ: INSY), Cannabis Sativa Inc. (OTC: CBDS), General Cannabis Corporation (OTC: CANN), Cara Therapeutics Inc. (NASDAQ: CARA).
Studies found in The Washington Post, pulmonologist Dr. Donald Tashkin, Professor Emeritus at the David Geffen School of Medicine at UCLA, has assumed that there would be a positive association between marijuana use and lung cancer, and that the association would be more positive with heavier use. What they found instead was no connection at all, and even a suggestion of some protective effect.
CV Sciences Inc. (OTCQB: CVSI) is currently in development of Cannabidiol-based potential U.S. Food and Drug Administration approved drugs. The company's pipeline is the CVSI-007, a chewing gum that contains nicotine and synthetic Cannabidiol to support cessation of smokeless tobacco use and addiction. CV Sciences currently has two distinct operations: the Pharmaceuticals and Consumer Products Divisions. These divisions are supported by its medical and scientific advisory board, and advanced art production facilities.
CV Sciences is involved in manufacturing, growth, distributing and marketing consumer products that contain plant-based cannabidiol, which is developed in its portfolio brand. PlusCBD Oil is the top-selling brand of hemp-derived CBD oil for customers in the natural products industry. It has built a name on product quality, safety and efficacy, presenting diverse and is the largest supply of hemp-derived CBD oil in the US. Purified Liquids is CV Sciences' latest addition in its portfolio, is the premium CBD vape e-liquids.
The company will be hosting a webcast regarding its clinical product pipeline Cannabidiol based drug development program on November 10th. The webcast will be discoursing its current program for the development of therapeutic products for cessation of smokeless tobacco use and addiction. This market is projected to surpass $2 billion in the United States alone. According to Statista, there were approximately $5.3 billion in retail sales of smokeless tobacco products in 2014, and roughly 1.3 billion smokeless tobacco products were sold during that time. Smokeless tobacco addiction is a huge unmet medical need, as there are currently no available FDA-approved drugs to treat this addiction.
Insys Therapeutics Inc. (NASDAQ: INSY) is currently undergoing Phase-2 clinical trials of the treatment for refractory infantile spasms by consuming cannabidiol oral solution. Infantile Spasms is a diagnosis described as a rare and terrible form of epilepsy that usually attacks children in the first year of life. According to the study, this is a multi-center study to evaluate the efficacy and safety of Cannabidiol Oral Solution (COS) in the treatment of children aged 6 months through 36 months with a diagnosis of infantile spasms who have not responded to first line therapies. The dose of Cannabidiol Oral Solution will begin at 20 mg/kg daily [10 mg/kg twice per day (BID)], will be adjusted at any time if the investigator feels the safety or well-being of the participant is at risk, and will be titrated up or down according to protocol-stipulated parameters and at the investigator's discretion after Day 14 to enhance efficacy. Dose will not exceed 40 mg/kg daily.
Cannabis Sativa Inc. (OTCQB: CBDS) subsidiary, Ibudtender, is anchoring a Prop 215 event in San Francisco's Cow Palace this Halloween. Ibudtender is currently the technology arm of Hempcon. The company will be featuring its Wild Earth Naturals cannabidiol infused water at the Ibudtender booth. Eventgoers are invited to Ibudtender's booth to check out its latest technology for the cannabis sector.
General Cannabis Corp. (OTCQB: CANN) resources for top service providers available to the regulated Cannabis Industry. CANN is a partner to the cultivation, production and retail side of the marijuana business. The company does this through a combination of operating divisions such as real estate, consulting, security, financing and the distribution of vital infrastructure products to cultivate facilities and dispensaries. As a holding company, its subsidiaries are able to leverage the strengths of each other to help improve its company.
Cara Therapeutics Inc. (NASDAQ: CARA) has studied the effects of cannabis leading to an endogenous system of ligands in individuals associated in a number of physiological processes that include pain and inflammation. Cara owns CR701, a subsidiary performing cannabinoid receptor pain drug and CR845, Cara's topmost pain treatment. The degree of kappa receptor selectivity displayed by CR845 ranks as best-in-class compared to all other previously developed compounds for this therapeutic target. Also, CR845 displayed no significant affinity for any other non-opioid known receptors.
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
For "The Latest Buzz in Financial News", SIGN UP & Visit: http://www.FinancialBuzz.com
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
For further information:
Media Contact: Danny A, email@example.com , +1-877-601-1879